{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:04:08Z","timestamp":1770998648407,"version":"3.50.1"},"reference-count":11,"publisher":"Impact Journals, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2012,4,30]]},"DOI":"10.18632\/oncotarget.488","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T21:49:58Z","timestamp":1442440198000},"page":"395-398","source":"Crossref","is-referenced-by-count":117,"title":["Metformin-induced preferential killing of breast cancer initiating CD44+CD24\u2212\/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts"],"prefix":"10.18632","volume":"3","author":[{"given":"S\u00edlvia","family":"Cuf\u00ed","sequence":"first","affiliation":[{"name":"Translational Research Laboratory, Catalan Institute of Oncology (ICO), Girona, Spain"},{"name":"Girona Biomedical Research Institute (IDIBGi), Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Corominas-Faja","sequence":"additional","affiliation":[{"name":"Translational Research Laboratory, Catalan Institute of Oncology (ICO), Girona, Spain"},{"name":"Girona Biomedical Research Institute (IDIBGi), Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Vazquez-Martin","sequence":"additional","affiliation":[{"name":"Translational Research Laboratory, Catalan Institute of Oncology (ICO), Girona, Spain"},{"name":"Girona Biomedical Research Institute (IDIBGi), Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Oliveras-Ferraros","sequence":"additional","affiliation":[{"name":"Translational Research Laboratory, Catalan Institute of Oncology (ICO), Girona, Spain"},{"name":"Girona Biomedical Research Institute (IDIBGi), Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Dorca","sequence":"additional","affiliation":[{"name":"Girona Biomedical Research Institute (IDIBGi), Girona, Spain"},{"name":"Medical Oncology, Catalan Institute of Oncology (ICO), Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Bosch-Barrera","sequence":"additional","affiliation":[{"name":"Girona Biomedical Research Institute (IDIBGi), Girona, Spain"},{"name":"Medical Oncology, Catalan Institute of Oncology (ICO), Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Martin-Castillo","sequence":"additional","affiliation":[{"name":"Girona Biomedical Research Institute (IDIBGi), Girona, Spain"},{"name":"Clinical Research Unit, Catalan Institute of Oncology (ICO), Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier A.","family":"Menendez","sequence":"additional","affiliation":[{"name":"Translational Research Laboratory, Catalan Institute of Oncology (ICO), Girona, Spain"},{"name":"Girona Biomedical Research Institute (IDIBGi), Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2012,5,4]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10911-009-9116-x","article-title":"Stemming resistance to HER-2 targeted therapy","volume":"14","author":"Piccart-Gebhart","year":"2009","journal-title":"J Mammary Gland Biol"},{"key":"2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbrc.2010.05.041","article-title":"Dynamic emergence of the mesenchymal CD44(pos)CD24(neg\/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin)","volume":"397","author":"Menendez","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"3","first-page":"12","article-title":"CD44+ CD24-\/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines","volume":"12","author":"Sotiriou","year":"2011","journal-title":"Pharmacogenomics"},{"key":"4","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Struhl","year":"2009","journal-title":"Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-010-0924-x","article-title":"The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells","volume":"126","author":"Menendez","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"6","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/0008-5472.CAN-10-3471","article-title":"Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types","volume":"71","author":"Struhl","year":"2011","journal-title":"Cancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1535-7163.1585.3.12","article-title":"Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer","volume":"3","author":"Isola","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cancergencyto.2006.09.014","article-title":"Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1","volume":"172","author":"Isola","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.canlet.2010.02.002","article-title":"Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells","volume":"294","author":"Isola","year":"2010","journal-title":"Cancer Lett"},{"key":"10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3892\/ijo_00000716","article-title":"Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin)","volume":"37","author":"Menendez","year":"2010","journal-title":"Int J Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/annonc\/mdp494","article-title":"Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology","volume":"21","author":"Menendez","year":"2010","journal-title":"Ann Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T06:20:33Z","timestamp":1691994033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,30]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["488","22565037"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.488","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,30]]}}}